The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Could Hidden Infections Be Fueling Long COVID?
- Join NJ ACTS BERD on 1/22 for a Workshop with Dr. Yan Sun from NJIT
- How NJIT Graduate Student Jaimee Diogo Is Transforming STEM Futures Through ‘STEM Like a Girl’
- New Study Reveals Progress in Hospital Maternity Care Access in New Jersey, with Opportunities for Continued Improvement.
- Submit Your Proposal for Clinical Trials Days 2026
Categories
- Community (2,425)
- Covid (995)
- CTO Events (6)
- News (3,071)
- Pilots (21)